Loading clinical trials...
Loading clinical trials...
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Conditions
Interventions
GTx-024
placebo
Locations
30
United States
GTx Investigative Site
Birmingham, Alabama, United States
GTx Investigative Site
Scottsdale, Arizona, United States
GTx Investigative Site
La Jolla, California, United States
GTx Investigative Site
Long Beach, California, United States
GTx Investigative Site
Miami, Florida, United States
GTx Investigative Site
Orange City, Florida, United States
Start Date
July 1, 2011
Primary Completion Date
May 1, 2013
Completion Date
June 1, 2014
Last Updated
November 9, 2020
NCT06758401
NCT07431827
NCT06427941
NCT06476808
NCT07164313
NCT05142189
Lead Sponsor
GTx
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions